- Home
- IPSC vs CNTB Comparison
IPSC vs CNTB Comparison
Compare IPSC & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- CNTB
- Stock Information
- Founded
- IPSC 2019
- CNTB 2012
- Country
- IPSC United States
- CNTB United States
- Employees
- IPSC N/A
- CNTB N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- IPSC Health Care
- CNTB Health Care
- Exchange
- IPSC Nasdaq
- CNTB Nasdaq
- Market Cap
- IPSC 47.4M
- CNTB 54.4M
- IPO Year
- IPSC 2021
- CNTB 2021
- Fundamental
- Price
- IPSC $0.59
- CNTB $1.46
- Analyst Decision
- IPSC Strong Buy
- CNTB Strong Buy
- Analyst Count
- IPSC 5
- CNTB 2
- Target Price
- IPSC $3.33
- CNTB $7.50
- AVG Volume (30 Days)
- IPSC 1.0M
- CNTB 148.9K
- Earning Date
- IPSC 08-07-2025
- CNTB 09-04-2025
- Dividend Yield
- IPSC N/A
- CNTB N/A
- EPS Growth
- IPSC N/A
- CNTB N/A
- EPS
- IPSC N/A
- CNTB N/A
- Revenue
- IPSC $114,898,000.00
- CNTB $26,033,000.00
- Revenue This Year
- IPSC $1,590.09
- CNTB N/A
- Revenue Next Year
- IPSC N/A
- CNTB N/A
- P/E Ratio
- IPSC N/A
- CNTB N/A
- Revenue Growth
- IPSC 8286.72
- CNTB N/A
- 52 Week Low
- IPSC $0.34
- CNTB $0.51
- 52 Week High
- IPSC $3.29
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- IPSC 55.59
- CNTB 72.56
- Support Level
- IPSC $0.59
- CNTB $1.05
- Resistance Level
- IPSC $0.57
- CNTB $1.56
- Average True Range (ATR)
- IPSC 0.04
- CNTB 0.13
- MACD
- IPSC 0.00
- CNTB 0.04
- Stochastic Oscillator
- IPSC 66.59
- CNTB 84.59
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.